Early Enhanced Expression of Interferon-Inducible Protein-10 (CXCL-10) and Other Chemokines Predicts Adverse Outcome in Severe Acute Respiratory Syndrome

Abstract Background: Exaggerated activation of cytokines/chemokines has been proposed as a factor in adverse outcome of severe acute respiratory syndrome (SARS). Previous studies on chemokines have included only small numbers of patients, and the utility of plasma chemokines as prognostic indicators is unclear. Methods: We studied 255 archival plasma samples collected during the first or second week after disease onset. The chemokines interferon-inducible protein-10 (IP-10), monokine induced by interferon-γ (MIG), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), and regulated upon activation normal T cell expressed and secreted (RANTES) were measured by cytometric bead array with a 4-color FACSCalibur flow cytometer. Reverse transcription and real-time quantitative PCR and immunohistochemical staining were performed to analyze the production of IP-10 in lung tissue at autopsy. Conditional logistic regression was used to identify independent predictors for adverse disease outcome. Results: Increases in IP-10, MIG, and IL-8 during the first week after onset of fever were associated with adverse outcome (intensive care unit admission or death) in the univariate analysis. During the second week, only MIG concentration was associated with prognosis. After adjusting for other risk factors, plasma IP-10 concentration at the first week remained as an independent prognostic factor, with an odds ratio for adverse outcome of 1.52 (95% confidence interval, 1.05–2.55) per fold increase in plasma IP-10 concentration above the median. During the second week, chemokines provided little independent prognostic information. IP-10 was increased in lung tissue from patients who died of SARS. Conclusions: Increased plasma IP-10 during the first week of SARS symptoms is an independent predictor of outcome. Chemokine activation may be an early event in SARS, and an exaggerated host response may produce complications.

[1]  S. Lai,et al.  Treatment of severe acute respiratory syndrome , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  S. Moochhala,et al.  Chemokines in acute respiratory distress syndrome , 2005, American journal of physiology. Lung cellular and molecular physiology.

[3]  Michel Theron,et al.  An interferon‐γ‐related cytokine storm in SARS patients† , 2004, Journal of medical virology.

[4]  J. F. Bermejo,et al.  Severe acute respiratory syndrome, a pathological immune response to the new coronavirus--implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology. , 2004, Viral immunology.

[5]  A. Mandavilli.  Immune response to SARS sets up puzzling paradox , 2004, Nature Medicine.

[6]  Pan‐Chyr Yang,et al.  Temporal Relationship of Viral Load, Ribavirin, Interleukin (IL)—6, IL-8, and Clinical Progression in Patients with Severe Acute Respiratory Syndrome , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  B. Murphy,et al.  Mechanisms of Host Defense following Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) Pulmonary Infection of Mice , 2004, The Journal of Immunology.

[8]  Jing Li,et al.  Analysis of Serum Cytokines in Patients with Severe Acute Respiratory Syndrome , 2004, Infection and Immunity.

[9]  M. Iturriza-Gómara,et al.  Laboratory diagnosis of SARS. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[10]  J. Chan,et al.  The spectrum of pathological changes in severe acute respiratory syndrome (SARS) , 2004, Histopathology.

[11]  R. Homer,et al.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.

[12]  A. Lo,et al.  Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS‐CoV) and its putative receptor, angiotensin‐converting enzyme 2 (ACE2) , 2004, The Journal of pathology.

[13]  V. Wong,et al.  Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak , 2004, Thorax.

[14]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.

[15]  J. Sung,et al.  Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS) , 2004, Journal of Clinical Pathology.

[16]  Janet S. Lee,et al.  Cytokine-mediated inflammation in acute lung injury. , 2003, Cytokine & growth factor reviews.

[17]  R. Rappuoli,et al.  SARS — beginning to understand a new virus , 2003, Nature Reviews Microbiology.

[18]  J. Sung,et al.  Quantitative Analysis and Prognostic Implication of SARS Coronavirus RNA in the Plasma and Serum of Patients with Severe Acute Respiratory Syndrome , 2003 .

[19]  O. Tsang,et al.  Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong , 2003, Annals of Internal Medicine.

[20]  M. Burdick,et al.  Role of CXCL9/CXCR3 Chemokine Biology during Pathogenesis of Acute Lung Allograft Rejection 1 , 2003, The Journal of Immunology.

[21]  S. Lai,et al.  Severe Acute Respiratory Syndrome: Clinical Outcome and Prognostic Correlates , 2003, Emerging infectious diseases.

[22]  Junya Fukuoka,et al.  Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore , 2003, Human Pathology.

[23]  Xin Li,et al.  The clinical pathology of severe acute respiratory syndrome (SARS): a report from China , 2003, The Journal of pathology.

[24]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[25]  R. Strieter,et al.  Host innate defenses in the lung: the role of cytokines , 2003, Current opinion in infectious diseases.

[26]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[27]  Yi Guan,et al.  Lung pathology of fatal severe acute respiratory syndrome , 2003, The Lancet.

[28]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[29]  C. Wong,et al.  Clinical applications of cytokine assays. , 2003, Advances in clinical chemistry.

[30]  L. Trentin,et al.  CXC chemokines IP-10 and mig expression and direct migration of pulmonary CD8+/CXCR3+ T cells in the lungs of patients with HIV infection and T-cell alveolitis. , 2000, American journal of respiratory and critical care medicine.

[31]  Q. Hamid,et al.  The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. , 1999, Journal of immunology.

[32]  G. Meduri,et al.  Infections and the inflammatory response in acute respiratory distress syndrome. , 1997, Chest.

[33]  R. Strieter,et al.  Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. , 1996, American journal of respiratory and critical care medicine.